On the role of anti-cN1A antibodies in sporadic inclusion body myositis and beyond: a challenging task full of surprises
Open Access
- 5 January 2024
- journal article
- editorial
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 61 (6) , 411-413
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case reportImmunologic Research, 2023
- Novel aspects of muscle involvement in immune-mediated inflammatory arthropathies and connective tissue diseasesAutoimmunity Reviews, 2023
- The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature reviewAutoimmunity Reviews, 2022
- Diagnostic Accuracy of Anti-CN1A on the Diagnosis of Inclusion Body Myositis. A Hierarchical Bivariate and Bayesian Meta-analysisJournal of Clinical Neuromuscular Disease, 2021
- Anti-cN1A Antibodies Are Associated with More Severe Dysphagia in Sporadic Inclusion Body MyositisCells, 2021
- Anti‐cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositisMuscle & Nerve, 2020
- Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung CancerMediterranean Journal of Rheumatology, 2020
- Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body MyositisFrontiers in Immunology, 2019
- Inclusion body myositis: clinical features and pathogenesisNature Reviews Rheumatology, 2019
- Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohortsClinica Chimica Acta, 2017